Related Experiment Video
Updated: Feb 18, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
1Pharmaceutical Technology Department, the German University in Cairo (GUC), Cairo,Egypt.
Background:
Multidrug resistance in cancer is the ability of a cancer cell to resist treatment with a wide range of structurally and functionally dissimilar chemotherapeutics. The resistant phenotype could arise in response to several cellular changes that ultimately result in a decrease in intracellular drug accumulation (or effectiveness), either by limiting cellular drug entry, or by expulsion of those molecules that have made it into the cell. Both blocking drug cellular entry and its expulsion are mostly brought about by the cell membrane. Several pharmaceutical excipients (mainly lipids, surfactants and amphililc copolymers) have been reported to reverse multidrug resistance by addressing cell membrane related changes resulting in low intracellular drug levels in resistant cells. These excipients are routinely used in the preparation of lipid based nanoparticles endowing inherent multidrug resistance reversing properties to these nanoparticles.
Methods:
In this review, cell membrane alterations resulting in multidrug resistance will be initially reviewed, followed by a discussion of the different types of lipid NPs and the potential held by the excipients used in their preparation in multidrug resistance reversal. Finally, a discussion on how lipid nanoparticles have been engineered and used in different occasions to enable multidrug resistance reversal is included.
Conclusion:
The superior role held by lipid nanoparticles in comparison to free excipients will be highlighted.
Insights
Pharmaceutical excipients in lipid nanoparticles can reverse cancer multidrug resistance by targeting cell membrane changes. Lipid nanoparticles show superior efficacy compared to free excipients in overcoming this resistance.
Area of Science:
- Oncology
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Multidrug resistance (MDR) in cancer involves cellular changes affecting drug accumulation.
- Cell membrane alterations, including drug entry blockage and expulsion, are key to MDR.
- Pharmaceutical excipients can reverse MDR by addressing cell membrane-related drug level changes.
Purpose of the Study:
- To review cell membrane alterations contributing to cancer multidrug resistance.
- To discuss lipid nanoparticles (NPs) and excipients for MDR reversal.
- To explore the engineering and application of lipid NPs in overcoming MDR.
Main Methods:
- Review of literature on cell membrane alterations in MDR.
- Analysis of different lipid NP formulations and their excipients.
- Discussion of engineered lipid NPs for MDR reversal applications.
Main Results:
- Excipients used in lipid NPs possess inherent MDR-reversing properties.
- Lipid nanoparticles can be engineered to effectively reverse multidrug resistance.
- Lipid nanoparticles demonstrate a significant role in overcoming cancer drug resistance.
Conclusions:
- Lipid nanoparticles are superior to free excipients in reversing multidrug resistance.
- Targeting cell membrane dynamics with lipid-based formulations is a promising strategy.
- Engineered lipid nanoparticles offer enhanced therapeutic potential against resistant cancers.
Related Concept Videos
Treatment Resistant Cancers
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bioavailability Enhancement: Drug Permeability Enhancement
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modified-Release Drug Delivery Systems: Site-Targeted

